Immunovant’s IMVT-1402 FcRn inhibitor produced “really great” responses in an ongoing Phase 2b open-label dataset in difficult-to-treat rheumatoid arthritis, according to CEO Matt Gline. Shares were reported up sharply as investors digested the 16-week findings across ACR20, ACR50, and ACR70 assessments in patients who had failed two or more prior advanced therapies. The study remains ongoing, and next steps include continuing processing of the dataset and engaging with the FDA on subsequent development strategy. The update comes amid a broader competitive set of FcRn inhibition efforts in autoimmune disease, where durability and safety profiles are key decision drivers. While early, the data set has immediate impact on sentiment around Immunovant’s ability to progress a next-generation immunology asset through late-stage milestones.